Ascelia Pharma update: Funded for near-term triggers ahead - Redeye

After the warrant contribution, Ascelia Pharma is well funded for 2025 with some SEK 80m net cash, which is enough for securing a partner ahead of the US launch in 2026 and completing the submission of Orviglance by the first half of August. If Ascelia can secure a strong US partner on good terms, our Base Case target price could be reached within three to twelve months.

Länk till analysen i sin helhet: https://www.redeye.se/research/1110096/ascelia-pharma-update-funded-for-near-term-triggers-ahead?utm_source=finwire&utm_medium=RSS